It has been reported that EZH2 is upregulated in multiple malignancies, such as breast cancer, prostate cancer, melanoma and ovarian cancer 5-9, where its oncogenic activity has been proven to be primarily mediated by silencing tumor suppressor genes 6, 10. This evidence concerns the gene EZH2 and breast carcinoma.